MDT

95.44

+0.22%↑

VEEV

294.39

+1.24%↑

A

142.08

+2.59%↑

HQY

92.37

-1.72%↓

TLRY

1.58

-1.25%↓

MDT

95.44

+0.22%↑

VEEV

294.39

+1.24%↑

A

142.08

+2.59%↑

HQY

92.37

-1.72%↓

TLRY

1.58

-1.25%↓

MDT

95.44

+0.22%↑

VEEV

294.39

+1.24%↑

A

142.08

+2.59%↑

HQY

92.37

-1.72%↓

TLRY

1.58

-1.25%↓

MDT

95.44

+0.22%↑

VEEV

294.39

+1.24%↑

A

142.08

+2.59%↑

HQY

92.37

-1.72%↓

TLRY

1.58

-1.25%↓

MDT

95.44

+0.22%↑

VEEV

294.39

+1.24%↑

A

142.08

+2.59%↑

HQY

92.37

-1.72%↓

TLRY

1.58

-1.25%↓

Search

PTC Therapeutics Inc

Open

SectorHealthcare

66.89 -2.25

Overview

Share price change

24h

Current

Min

66.33

Max

69.15

Key metrics

By Trading Economics

Income

-931M

-65M

Sales

-997M

179M

P/E

Sector Avg

9.37

36.442

Profit margin

-36.254

Employees

939

EBITDA

-1B

-35M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

-0.33% downside

Dividends

By Dow Jones

Next Earnings

6 lis 2025

Market Stats

By TradingEconomics

Market Cap

1.1B

5.3B

Previous open

69.14

Previous close

66.89

News Sentiment

By Acuity

10%

90%

6 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

PTC Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 lip 2025, 16:40 UTC

Major Market Movers

PTC Therapeutics Gains on FDA Approval for Blood-Disorder Treatment

2 gru 2024, 12:47 UTC

Major Market Movers

PTC Therapeutics Shares Jump on Pact With Novartis

Peer Comparison

Price change

PTC Therapeutics Inc Forecast

Price Target

By TipRanks

-0.33% downside

12 Months Forecast

Average 65.87 USD  -0.33%

High 118 USD

Low 44 USD

Based on 17 Wall Street analysts offering 12 month price targets forPTC Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

17 ratings

11

Buy

5

Hold

1

Sell

Technical Score

By Trading Central

40.81 / 50.39Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

6 / 371 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
help-icon Live chat